Gain-of-function mutations in the TM6–TM7 transmembrane region of CASR drive ADH1 by increasing receptor sensitivity to calcium, lowering the PTH suppression threshold, and causing hypocalcemia with low PTH and hypercalciuria. The gene discussed is PTH; the disease is Hypercalciuria.